Evidence map›Paper›PMID 30952918›Full record

Trial reportScientific reports2019

Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease.

Sang Bong Ahn, Dae Won Jun, Bo-Kyeong Kang, Jong Hyun Lim, Sanghyun Lim, Myung-Jun Chung

2 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 124 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 15 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05885373 nacompletednot on this mapstarted 2023, after this paper: background citation

A Single-arm, Open-label Clinical Study to Evaluate the Effect of SIM01 in Female Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

TypeinterventionalSponsorGenieBiome LimitedRan2023 to 2023Enrolled40ConditionsNon-Alcoholic Fatty Liver DiseaseArmsSIM01
NCT06491342 nacompletednot on this mapstarted 2024, after this paper: background citation

Probiotic supplement versus placebo for decrease steatosis in metabolic dysfunction-associated steatotic liver disease (masld): a multicenter, randomized, double-blind, placebo-controlled trial

TypeinterventionalSponsorPhramongkutklao College of Medicine and HospitalRan2024 to 2025Enrolled90ConditionsFatty Liver, NonalcoholicArmsProbiotic, Placebo
3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 15 syntheses or guidelines pooled it, 203 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease.Computational and mathematical methods in medicine · 2022
    Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Plant-DerivedNutrients · 2022
    Trial
  20. Trial

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Sang Bong AhnDepartment of Internal Medicine, Eulji University School of Medicine, Seoul, Korea.
Dae Won JunDepartment of Internal Medicine, Hanyang University School of Medicine, Hanyang University Medical Center, Seoul, Korea. noshin@hanyang.ac.kr.ORCID http://orcid.org/0000-0002-2875-6139
Bo-Kyeong KangDepartment of Radiology, Hanyang University School of Medicine, Hanyang University Medical Center, Seoul, Korea. dr.bokyeong.kang@gmail.com.
Jong Hyun LimR&D center Microbiome, Cell Biotech, Gyeongi, Korea.
Sanghyun LimR&D center Microbiome, Cell Biotech, Gyeongi, Korea.
Myung-Jun ChungR&D center Microbiome, Cell Biotech, Gyeongi, Korea.
Cell Biotech (South Korea) · KRHanyang University Medical Center · KREulji University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The intestinal microbiota is closely associated with the development of obesity and nonalcoholic fatty liver disease (NAFLD). This study investigated the effects of probiotic treatment on visceral fat area (VFA) and intrahepatic fat (IHF) fraction in NAFLD. Sixty-eight obese NAFLD patients (>5% proton density fat fraction [PDFF] on magnetic resonance imaging [MRI]) were randomized to probiotic and placebo groups for 12 weeks. The probiotic mixture included 6 bacterial species. VFA and IHF were measured using the MRI-PDFF technique. Body weight and total body fat were reduced in the probiotic group but not in the placebo group. The mean IHF fraction was reduced after 12 weeks of treatment in the probiotic group compared to that at baseline (from 16.3 ± 15.0% to 14.1 ± 7.7%, p = 0.032) but was not reduced in the placebo group. The decrease in IHF (mean difference: -2.61%, p = 0.012) was also greater in the probiotic group than in the placebo group. Reduction of triglyceride was greater in the probiotic treatment group than in the placebo group (mean difference: -34.0 mg/dl, p = 0.0033). However, the changes in IHF percentage and triglyceride levels were not different between placebo and control groups after adjusting for changes in body weight. Treatment with probiotics for 12 weeks resulted in significant reduction in IHF and body weight in obese NAFLD patients.

Indexed as

Adipose TissueAdultAgedDouble-Blind MethodFemaleHumansLiverMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseProbioticsTriglyceridesYoung AdultTriglycerides

Identifiers

PMID30952918
PMCPMC6450966
OpenAlexW2929885060

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.